Skip to main content
. 2012 Dec 4;2(12):e201. doi: 10.1038/tp.2012.125

Table 1a. Clinical and serological status according to HERV-W RNA transcriptional level (HERV+ and HERV−).

  BD
SZ
  N used (±) HERV+ (N=51) HERV− (N=40) P-value N used (±) HERV+ (N=17) HERV−(N=28) P-value
Age at onset (years±s.d. ) 48/39 25.83 (8.6) 27.28 (11.6) 0.931 16/26 24.06 (10) 23.65 (5.8) 0.773
Age at interview (years±s.d.) 49/40 44.55 (12) 42.9 (13.2) 0.723 16/25 33.93 (11.1) 35.28 (11.3) 0.749
Duration of illness (years±s.d.) 49/39 18.30 (11.9) 15.17 (10.1) 0.220 16/25 9.88 (6.4) 11.6 (10.5) 0.952
Number of episodes 43/39 8.62 (6.3) 8.33 (7.8) 0.270 15/24 4.10 (3.1) 4.12 (3) 0.898
MADRS (mean scores) 49/40 6.18 (9.1) 6.98 (8.9) 0.792        
YMRS (mean scores) 49/39 4.50 (7.1) 5.43 (7.8) 0.727        
PANSS (mean total scores) 45/35 37.13 (11.5) 38.94 (13.3) 0.896 15/20 65.93 (20.9) 65.1 (15.1) 0.469

Abbreviations: BD, (patients with) bipolar disorder; HERV-W, Human Endogenous Retrovirus type-W; MADRS, Montgomery and Asberg Depression Rating Scale; PANSS, Positive And Negative Syndrome Scale; SZ, (patients with) schizophrenia;YMRS, Young Mania Rating Scale.

HERV-W expression status among patients with BD and SZ.

HERV-W ‘Positives' have a transcriptional level with RNA copy number significantly elevated, compared with background transcription in healthy controls; ‘Negatives' have RNA copy number below the threshold (see Patients and methods).

As few samples could not be tested for all parameters (insufficient volume, quality control not passed, and so on) the numbers effectively tested and used for calculations presented in Table 1a are indicated in columns with ‘N used (±)'.